Sorrento Therapeutics, Inc.
SRNE · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$577,757 | -$429,138 | -$314,410 | -$363,012 |
| Dep. & Amort. | $13,245 | $12,462 | $11,007 | $10,989 |
| Deferred Tax | -$1,836 | -$35,927 | -$2,125 | -$373 |
| Stock-Based Comp. | $74,847 | $90,188 | $31,419 | $12,648 |
| Change in WC | $69,551 | -$2,791 | $3,799 | $7,248 |
| Other Non-Cash | $128,093 | $83,385 | $110,774 | $159,504 |
| Operating Cash Flow | -$293,857 | -$281,821 | -$159,536 | -$172,996 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$13,657 | -$8,871 | -$37,579 | -$11,442 |
| Net Acquisitions | -$14,861 | -$754 | -$2,344 | -$9,691 |
| Inv. Purchases | $0 | -$35,295 | $0 | -$9,691 |
| Inv. Sales/Matur. | $0 | $124,767 | $0 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | -$7,349 |
| Investing Cash Flow | -$28,518 | $79,847 | -$39,923 | -$38,173 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$92,240 | -$35,913 | -$186,977 | $22,337 |
| Stock Issued | $402,334 | $201,825 | $317,865 | $47,697 |
| Stock Repurch. | $0 | $0 | -$55,000 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $1,624 | $15,420 | $98,351 | $8,851 |
| Financing Cash Flow | $311,718 | $181,332 | $174,239 | $78,885 |
| Forex Effect | -$2,374 | $843 | $915 | -$277 |
| Net Chg. in Cash | -$13,031 | -$19,799 | -$24,305 | -$132,561 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $36,665 | $56,464 | $80,769 | $213,330 |
| End Cash | $23,634 | $36,665 | $56,464 | $80,769 |
| Free Cash Flow | -$307,514 | -$290,692 | -$197,115 | -$184,438 |